

## DAFTAR PUSTAKA

1. Passie, Torsten., Seifert, Juergen., Schneider, Udo and M. Emrich, Hinderk. The Pharmacology of Psilocybin. [homepage on internet]. Available from: <http://files.shroomery.org/cms/4529203-pharmacologyofpsilocybin.pdf> (accessed 2002)
2. Setyabudi, Nugroho. Mabuk Jamur Mushroom, Mahasiswa Undip Ngamuk & Tewas. [homepage on internet]. Available from: <http://jogja.okezone.com/read/2012/11/17/512/719612/mabuk-jamur-mushroom-mahasiswa-undip-ngamuk-tewas> (accessed 2012)
3. Supradja, IGNA. Hasil wawancara/survai di Bali (Kuta, Sanur dan sekitarnya) tentang Penggunaan Jamur Panaeolus ini (“ Magic Mushroom”) dalam hidangan “Special Ommelet”, 1985
4. Walker, Jim I. Different Psilocybin Species. [homepage on internet]. Available from: [http://www.erowid.org/plants/mushrooms/mushrooms\\_info8.shtml](http://www.erowid.org/plants/mushrooms/mushrooms_info8.shtml) (accessed 1994)
5. Gartz, Jochen. Extraction and Analysis of Indole Derivatives From Fungal Biomass. [homepage on internet]. Available from: [http://www.erowid.org/plants/mushrooms/mushrooms\\_journal1.shtml](http://www.erowid.org/plants/mushrooms/mushrooms_journal1.shtml) (accessed 1994)
6. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. "Acute psychological and physiological effects of psilocybin in healthy humans: a

- double-blind, placebo-controlled dose-effect study". *Psychopharmacology* 172 (2); 2004. p.145–56
7. Erowid. Psilocybin, Psilocin, and Magic Mushrooms Dose [homepage on internet]. Available from: [http://www.erowid.org/plants/mushrooms/mushrooms\\_dose.shtml](http://www.erowid.org/plants/mushrooms/mushrooms_dose.shtml)
  8. Gartz J. "New aspects of the occurrence, chemistry and cultivation of European hallucinogenic mushrooms". *Supplemento agli Annali dei Musei Civici di Rovereto Sezione Archeologica, Storia e Scienze Naturali* 8; 1992. p.107–24
  9. Gartz J. *Narrenschaemme. Psychotrope Pilze di Europa di Europa. Herausforderung sebuah Wertsystem und Forschung. Editions Heuwinkel. Genf / Neualschwill, 1993*
  10. Beug MW, Bigwood J. Psilosibin and psilosin level in twenty generations multiple species of wild mushrooms in the Pacific Northwest. *USAJ Ethnopharm* 5; 1982. p.271-289
  11. Gartz J. Biotransformasi derivatif tryptamine dalam budaya miselium *Psilocybe*. *J. Dasar Microbiol* 29; 1989. p.347-352
  12. Gartz J. Biotransformasi tryptamine dalam miselia berbuah *cubensis* *Psilocybe*. *Planta Med* 55; 1989. p.249-250
  13. Sottolano SM, Lurie IS. Quantitation of psilocybin in hallucinogenic mushrooms using high performance liquid chromatography. *J. Forensik Sci* 28; 1983. p.931-935

14. Casale JF. An organic-water extraction method for the isolation and identification of psilocin from hallucinogenic mushrooms. *J. Forensik Sci* 30; 1985. p.247-250
15. Kysilka R, Wurst M. A new extraction procedure for psilocybin and psilocin determination in mushroom samples. *Planta Med* 56; 1990. p.327-328
16. Wurst M, Kysilka R, Koza T. Analysis and indole alkaloid isolation mushroom by high performance liquid chromatography. *J. Chromatogr* 593; 1992. p.201-208
17. Hasler F, Bourquin D, Brenneisen R, Vollenweider FX. Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. *J Pharm Biomed Anal* 30; 2002. p.331-9
18. Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX. Psilocybin impairs high-level but not low-level motion perception. *Neuroreport* 15; 2004. p.1947-1951.
19. Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man - a PET study with [<sup>11</sup>C]raclopride. *Neuropsychopharmacology* 20; 1999. p.424-33
20. Carter OL, Pettigrew JD, Burr DC, Alais D, Hasler F, Vollenweider FX. Psilocybin impairs high-level but not low-level motion perception. *Neuroreport* 15; 2004. p.1947-51

21. Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX. Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT<sub>2A</sub> and 5-HT<sub>1A</sub> agonist psilocybin, 2005
22. Erowid. Psilocybin Mushrooms. [homepage on internet]. Available from: [http://www.erowid.org/plants/mushrooms/mushrooms\\_effects.shtml](http://www.erowid.org/plants/mushrooms/mushrooms_effects.shtml) (accessed 1997)
23. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar KA, Hermle L, Bull U, Sass H. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and dmethamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. *Neuropsychopharmacology* 20; 1999. p.565-81
24. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. *Neuropsychopharmacology* 16; 1997. p.357-72
25. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. "Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action". *NeuroReport* 9 (17); 1998. p.3897–902
26. Carhart-Harris RL, Nutt DJ. "User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study". *Journal of Substance Abuse* 15 (4); 2010. p.283–300

27. Van Amsterdam J, Opperhuizen A, van den Brink W. ["Harm potential of magic mushroom use: a review"](#). *Regulatory Toxicology and Pharmacology* 59 (3); 2011. p.423–9.
28. Simeon D. "Depersonalisation disorder: a contemporary overview". *CNS Drugs* 18 (6); 2004. p.343–54
29. Peden NR, Pringle SD. Hallucinogenic fungi. *Lancet* 1; 1982. p.396-7
30. Strassman RJ. Adverse reactions to psychedelic drugs. A review of the literature. *J Nerv Ment Dis* 172; 1984. p.577-95
31. Nichols CD, Sanders-Bush E. Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of MAP kinase phosphatase-1, C/EBP-beta and ILAD-1, a novel gene with homology to arrestins. *J Neurochem* 90; 2004. p.576-84
32. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R. Dose-response study of N,Ndimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. *Arch Gen Psychiatry* 51; 1994. P.98-108
33. World health organization. General guidelines for methodologies on research and evaluation of traditional medicine [homepage on internet]. Geneva: WHO; 2001
34. Reigner B, Blesch K. Estimating the starting dose for entry into humans: principles and practice. *European Journal of Clinical Pharmacology* 57(12); 2002. p.835-845

Lampiran 1. *Ethical clearance*



**KOMISI ETIK PENELITIAN KESEHATAN (KEPK)  
FAKULTAS KEDOKTERAN UNIVERSITAS DIPONEGORO  
DAN RSUP dr KARIADI SEMARANG**  
Sekretariat : Kantor Dekanat FK Undip Lt.3  
Jl. Dr. Soetomo 18. Semarang  
Telp.024-8311523/Fax. 024-8446905



**ETHICAL CLEARANCE**  
**No.223 /EC/FK/RSDK/2013**

Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Diponegoro/ RSUP. dr. Kariadi Semarang, setelah membaca dan menelaah USULAN Penelitian dengan judul :

**PENGARUH PEMBERIAN EKSTRAK JAMUR PSILOCYBE CUBENSIS  
DOSIS BERTINGKAT TERHADAP AKTIVITAS MOTORIK MENCIT SWISS WEBSTER  
DENGAN METODE ROTAROD MANUAL**

Peneliti Utama : Orieza Sativa Novitaloka  
Pembimbing : 1. dr. Sigid Kirana Lintang Bima, Sp.F  
2. dr. Tuntas Dhanardhono, M.Si.Med  
Penelitian : Dilaksanakan di Laboratorium Forensik FK Undip  
Cabang Semarang untuk pengandangan  
hewan dan uji pada hewan coba

Setuju untuk dilaksanakan, dengan memperhatikan prinsip-prinsip yang dinyatakan dalam Deklarasi Helsinki 1975, yang diamended di Seoul 2008 dan Pedoman Nasional Etik Penelitian Kesehatan (PNEPK) Departemen Kesehatan RI 2011

Pada laporan akhir peneliti harus melampirkan cara pemeliharaan & dekapitasi hewan coba

Semarang, 24 Mei 2013



Komisi Etik Penelitian Kesehatan  
Fakultas Kedokteran Undip/RSUP Dr. Kariadi  
Ketua,  
Prof.Dr.dr.Suprihati, M.Sc, Sp.THT-KL(K)  
NIP. 19500621197703 2 001

## Lampiran 2. Cara perhitungan dosis

1. Besar dosis jamur *Psilocybe cubensis* dosis ringan pada manusia 0,25 gram - 1 gram, dosis sedang dosisnya adalah 1 gram - 2,5 gram dan dosis berat adalah 2,5 gram - 5 gram.
2. Rumus yang biasa di gunakan adalah Human Equivalent Doses (HED dalam mg / kg) = Dosis Hewan (mg / kg) × Hewan Km ÷ Km Manusia.
3. Maka, di dapatkan dosis hewan dengan besar KM pada mencit adalah 3, yaitu:

1) Dosis ringan:

$$\text{PAD: } \frac{0,06 \times 37}{3} = 0,74 \sim 0,75 \text{ g/kg}$$

2) Dosis sedang:

$$\text{PAD: } \frac{0,12 \times 37}{3} = 1,48 \sim 1,5 \text{ g/kg}$$

3) Dosis berat:

$$\text{PAD: } \frac{0,24 \times 37}{3} = 2,96 \sim 3 \text{ g/kg}$$

**Lampiran 3.** Hasil analisis pengamatan aktivitas motorik mensit swiss webster dengan metode rotarod manual

## Explore

### kelompok mencit

Case Processing Summary

		Cases					
		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
skor aktivitas motorik	kelompok mencit						
	kelompok kontrol	5	100,0%	0	,0%	5	100,0%
	kelompok perlakuan dosis rendah 0,75gr/kg	5	100,0%	0	,0%	5	100,0%
	kelompok perlakuan dosis sedang 1,5gr/kg	5	100,0%	0	,0%	5	100,0%
	kelompok perlakuan dosis tinggi 3gr/kg	5	100,0%	0	,0%	5	100,0%



## Descriptives

kelompok mencit			Statistic	Std. Error
skor aktivitas motorik	kelompok kontrol	Mean	444,00	3,114
		95% Confidence Interval for Mean	435,35	
		Lower Bound		
		Upper Bound	452,65	
		5% Trimmed Mean	443,83	
		Median	442,00	
		Variance	48,500	
		Std. Deviation	6,964	
		Minimum	437	
		Maximum	454	
		Range	17	
		Interquartile Range	13	
		Skewness	,725	,913
		Kurtosis	-,933	2,000
kelompok perlakuan dosis rendah 0,75gr/kg		Mean	349,20	5,398
		95% Confidence Interval for Mean	334,21	
		Lower Bound		
		Upper Bound	364,19	
		5% Trimmed Mean	349,50	
		Median	353,00	
		Variance	145,700	
		Std. Deviation	12,071	
		Minimum	331	
		Maximum	362	
		Range	31	
		Interquartile Range	22	
		Skewness	-,877	,913
		Kurtosis	,223	2,000
kelompok perlakuan dosis sedang 1,5gr/kg		Mean	305,00	7,855
		95% Confidence Interval for Mean	283,19	
		Lower Bound		
		Upper Bound	326,81	
		5% Trimmed Mean	304,94	
		Median	305,00	
		Variance	308,500	
		Std. Deviation	17,564	
		Minimum	283	
		Maximum	328	
		Range	45	
		Interquartile Range	33	
		Skewness	,091	,913
		Kurtosis	-,924	2,000
kelompok perlakuan dosis tinggi 3gr/kg		Mean	231,40	4,523
		95% Confidence Interval for Mean	218,84	
		Lower Bound		
		Upper Bound	243,96	
		5% Trimmed Mean	231,61	
		Median	233,00	
		Variance	102,300	
		Std. Deviation	10,114	
		Minimum	217	
		Maximum	242	
		Range	25	
		Interquartile Range	19	
		Skewness	-,608	,913
		Kurtosis	-,855	2,000


## Tests of Normality

kelompok mencit		Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
skor aktivitas motorik	kelompok kontrol	,213	5	,200*	,935	5	,634
	kelompok perlakuan dosis rendah 0,75gr/kg	,224	5	,200*	,948	5	,720
	kelompok perlakuan dosis sedang 1,5gr/kg	,134	5	,200*	,991	5	,984
	kelompok perlakuan dosis tinggi 3gr/kg	,174	5	,200*	,954	5	,763

\*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

## skor aktivitas motorik



## T-Test

### Group Statistics

kelompok mencit		N	Mean	Std. Deviation	Std. Error Mean
skor aktivitas motorik	kelompok kontrol	5	444,00	6,964	3,114
	kelompok perlakuan dosis rendah 0,75gr/kg	5	349,20	12,071	5,398

### Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
skor aktivitas motorik	Equal variances assumed	1,554	,248	15,211	8	,000	94,800	6,232	80,429	109,171
	Equal variances not assumed			15,211	6,397	,000	94,800	6,232	79,777	109,823

## T-Test

### Group Statistics

kelompok mencit		N	Mean	Std. Deviation	Std. Error Mean
skor aktivitas motorik	kelompok kontrol	5	444,00	6,964	3,114
	kelompok perlakuan dosis sedang 1,5gr/kg	5	305,00	17,564	7,855

### Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
skor aktivitas motorik	Equal variances assumed	2,888	,128	16,450	8	,000	139,000	8,450	119,515	158,485
	Equal variances not assumed			16,450	5,227	,000	139,000	8,450	117,560	160,440


## T-Test

### Group Statistics

kelompok menci	N	Mean	Std. Deviation	Std. Error Mean
skor aktivitas motorik kelompok kontrol	5	444,00	6,964	3,114
kelompok perlakuan dosis tinggi 3gr/kg	5	231,40	10,114	4,523

### Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
skor aktivitas motorik	Equal variances assumed	,811	,394	38,712	8	,000	212,600	5,492	199,936	225,264
	Equal variances not assumed			38,712	7,097	,000	212,600	5,492	199,650	225,550

**Lampiran 4. Dokumentasi penelitian**

Gambar 7. Proses penelitian

- a. Rotarod manual yang digunakan
- b. Pengandangan dan proses adaptasi mencit selama 7 hari
- c. Serbuk jamur *Psilocybe cubensis*
- d. Proses pembuatan infusa

**Lampiran 5.** Biodata mahasiswa**Identitas**

Nama : Orieza Sativa Novitaloka  
NIM : G2A009192  
Tempat/tanggal lahir : Semarang/14 November 1992  
Jenis kelamin : Perempuan  
Alamat : Perum Rumpun Diponegoro Jl. Bangau IV/54 Semarang  
Nomor HP : 085641401992  
e-mail : [orieza.sativa@yahoo.com](mailto:orieza.sativa@yahoo.com)

**Riwayat Pendidikan Formal**

1. SD : SD Negeri Jomblang 02 Semarang Lulus tahun: 2004
2. SMP : SMP Negeri 9 Semarang Lulus tahun: 2007
3. SMA : SMA Negeri 1 Semarang Lulus tahun: 2009
4. S1 : Fakultas Kedokteran Universitas Diponegoro Masuk tahun:2009